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Abstract
Background: Aspirin-exacerbated respiratory disease (AERD) is a distinct eosinophilic phenotype of severe asthma
with accompanying chronic rhinosinusitis, nasal polyposis, and hypersensitivity to aspirin. Urinary 3-bromotyrosine
(uBrTyr) is a noninvasive marker of eosinophil-catalyzed protein oxidation. The lack of in vitro diagnostic test makes
the diagnosis of AERD difficult. We aimed to determine uBrTyr levels in patients with AERD (n = 240) and aspirin-
tolerant asthma (ATA) (n = 226) and to assess whether its addition to urinary leukotriene E4 (uLTE4) levels and blood
eosinophilia can improve the prediction of AERD diagnosis.
Methods: Clinical data, spirometry and blood eosinophilis were evaluated. UBrTyr and uLTE4 levels were measured
in urine by HPLC and ELISA, respectively.
Results: Both groups of asthmatics (AERD, n = 240; ATA, n = 226) had significantly higher uBrTyr, uLTE4 levels, and
blood eosinophils than healthy controls (HC) (n = 71) (p < 0.05). ULTE4 levels and blood eosinophils were significantly
higher in AERD as compared to ATA (p = 0.004, p < 0.0001, respectively). whereas uBrTyr levels were not significantly
different between both asthma phenotypes (p = 0.34). Asthmatics with high levels of uBrTyr (> 0.101 ng/mg Cr), uLTE4
levels (> 800 pg/mg Cr) and blood eosinophils (> 300 cells/ul) were 7 times more likely to have AERD.. However, uBrTyr
did not increase the benefit for predicting AERD when uLTE4 and blood eosinophils were already taken into
account (p = 0.57).
Conclusion: UBrTyr levels are elevated both in AERD and ATA as compared to HC, but they could not differentiate
between these asthma phenotypes suggesting a similar eosinophilic activation. The addition of uBrTyr to elevated
uLTE4 levels and blood eosinophils did not statistically enhance the prediction of AERD diagnosis.
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Background
Around 7% of asthmatics are hypersensitive to aspirin
and other non-steroidal anti-inflammatory drugs (NSAIDs)
[1]. This asthma phenotype, referred to as Aspirin-Exacer-
bated Respiratory Disease (AERD), is characterized by the
presence of usually severe asthma, chronic rhinosinusitis
with nasal polyposis, and acute asthma attacks with
naso-ocular symptoms after ingestion of aspirin and other
NSAIDs [2]. Previous studies have shown that patients
with AERD have increased emergency department visits,
hospitalizations, and corticosteroid bursts compared to
those with aspirin-tolerant asthma (ATA) [3, 4]. About
half of AERD patients have severe asthma that requires
chronic treatment with high dose of inhaled corticoste-
roids or oral corticosteroids to control the disease [4, 5].
AERD is an inflammatory condition of the upper and
lower airway characterized by increased eosinophils and
mast cells. Mechanistic studies have shown that AERD
is linked to abnormalities/dysregulation of the cyclooxy-
genase (COX) and lipooxygenase (LOX) pathway [2, 6].
It has been suggested that abnormal regulation of
5-LOX and leukotriene C4 synthase (LTC4S) pathways
that results in increased production of cysteinyl leukotri-
enes (CysLTs) leads to asthmatic attacks [2, 7, 8]. Urin-
ary leukotriene E4 (uLTE4), a stable CysLTs metabolite,
is used to measure their systemic production [9] and can
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be helpful in differentiating AERD from ATA [10, 11].
Sources of LTE4 include many cells of the upper and
lower airways such as eosinophils, mast cells, baso-
phils, as well as macrophages, platelets, and neutro-
phils [12].
Eosinophils are important effector cells in asthma and
even more so in AERD. Blood eosinophilia is well-recog-
nized biomarker of active inflammation in asthma [13,
14]. Activated eosinophils degranulate to release among
others eosinophil peroxidase (EPO), which is unique in its
ability to convert respiratory burst-generated hydrogen
peroxide into hypobromous acid, a reactive brominating
oxidant that modifies protein tyrosine residues, forming
3-bromotyrosine (BrTyr) [15, 16]. BrTyr, a biochemical
fingerprint of eosinophil activation as a highly stable prod-
uct can be detected in urine.
Currently, oral aspirin challenge is the gold standard
to confirm the diagnosis of AERD [17, 18]. However, this
test is time-consuming, can cause adverse reactions, and
is unsuitable in severe asthma patients [17]. Therefore,
noninvasive methods that could assist in diagnosis are
urgently needed.
To our knowledge, there is no generally recognized,
clinically available in vitro test or biomarker to deter-
mine the presence of AERD.
The purpose of this study was to determine uBrTyr
levels in patients with AERD and ATA and to explore if
uBrTyr might predict AERD. Moreover, we wanted to
test whether adding elevated uBrTyr levels to elevated
uLTE4 levels and blood eosinophil counts could improve
the prediction of AERD.
Methods
Study population
Patients with asthma were recruited from the outpatient
clinic of the Department of Internal Medicine, Jagiello-
nian University Medical College, Krakow. All patients
were clinically stable without any asthma exacerbations
within the 6 weeks preceding the study. All data and
sample collection have been previously described [11].
The diagnosis of AERD was determined through typ-
ical clinical presentation and at least 1 asthma attack
after ingestion of aspirin or another NSAID in the past.
This diagnosis was confirmed by a positive aspirin chal-
lenge in the majority of patients. However, clinical safety
limitation prohibited a small group of AERD patients
(16.7%, n = 40)) with very severe asthma to undergo as-
pirin challenge. Their aspirin hypersensitivity was con-
firmed based on their medical history with previous
reactions related to ingestion of NSAIDs well documented
in medical records. Removal of these severe asthmatics
could introduce additional bias in characteristics of AERD
phenotype, for which severe steroid dependent asthma is
very typical.
All ATA patients had used aspirin without any adverse
effects. Healthy control subjects (HC) without history of
asthma, allergy, and any hypersensitivity reactions to
NSAIDs were enrolled for comparison of baseline values
of inflammatory biomarkers.
Written informed consent was obtained from all par-
ticipants under a protocol approved by the Jagiellonian
University Ethics Review Committee.
Evaluation of asthma was determined by the National
Asthma Education and Prevention Program (NAEPP)
EPR-3 guidelines [19].
Asthma control was assessed by the Asthma Control
Test (ACT) [20].
Study procedures
Spirometry (MasterScreen, Jaeger, Wurzburg, Germany)
was carried out at baseline and after administration of 4
puffs of salbutamol. The best of 3 repeatable forced ex-
piratory maneuvers was recorded. The percent predicted
values of FEV1 and FEV1/FVC were automatically
calculated.
Blood eosinophil counts were calculated using a
Fuchs-Rosenthal chamber.
Urine analysis
Morning urine samples were collected after a 2 h accu-
mulation of urine in the bladder which allows for less
variation in urine creatinine levels [10].
Urine creatinine was measured by enzymatic method
using automated chemical analyzer COBAS Integra 400
plus (Roche Diagnostics USA, Indianapolis, IN).
Urinary BrTyr was assayed using stable isotope dilu-
tion High Performance Liquid Chromatography (HPLC)
with on-line electrospray ionization tandem mass spec-
trometry. First, a solid phase extraction was performed.
Briefly 20 μl internal standard composed of 0.5 μM syn-
thetic [13C6]-3-bromotyrosine, 1 mM [
13C9,
15N] tyro-
sine, and 1 mM creatinine-d3 (Cambridge Isotope
Laboratories) was spiked into 200 μl urine followed by
acidification with 1 ml 0.1% formic acid. The acidified
urine was loaded to a Biotage® auto solid phase extrac-
tion system with 3 ml DSC- 18 column used. DSC-18
column was balanced with 2 × 3 ml methanol and then
2 × 3 ml 0.1% formic acid, washed with 2 × 3 ml 0.1%
formic acid, and the product was eluated with 3 ml 0.1%
formic acid in 30% methanol. The product was dried
under SpeedVacuum, and then resuspended in 100 μl
H2O. Secondly, LC/MS/MS was used to quantify urinary
BrTyr. Five microliters of the extraction was analyzed by
injection onto a Titan™ C18 UHPLC Column (1.9 μm
particle size, L × I.D. 10 cm × 2.1 mm, Supelco) at a flow
rate of 0.4 ml min− 1 using a 2 Shimadzu LC-20 AD
Nexera CL pump system, SIL-30 AC MP CL autosam-
pler interfaced with an Shimadzu 8050 mass
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spectrometer. A discontinuous gradient was generated
to resolve the analytes by mixing solvent A (0.2% formic
acid in water) with solvent B (0.2% formic acid in metha-
nol) at different ratios starting from 0% B for 3 min,
then linearly to 100% B over 3.5 min, then hold for
3 min, and then back to 0% B. [13C9,
15N1]-tyrosine was
included to simultaneously monitor for potential artifi-
cial generation of analyte. 3-bromotyrosine, creatinine,
and their respective internal standards [13C6]-3-bromo-
tyrosine and creatinine-d3 were monitored using electro-
spray ionization in positive-ion mode with multiple
reaction monitoring (MRM) of precursor and character-
istic product-ion transitions of m/z 260→ 135, 114→
44, 266→ 141 and 117→ 47 amu, respectively. The pa-
rameters for the ion monitoring were optimized auto-
matically. Nitrogen (99.95% purity) was used as the
source, and helium was used as collision gas. Various con-
centrations of nonisotopically-labeled 3-bromotyrosine
were spiked into control urine to prepare the calibration
curves for quantification of 3-bromotyrosine. The internal
standard [13C6]-3-bromotyrosine was used for quantifica-
tion as well as to calculate recovery rate of TMAO (which
was > 80% based on separate control studies). Under the
conditions employed for the assay, no artificial bromina-
tion was detected. Results of urinary BrTyr were expressed
in nanograms per mg of creatinine.
ULTE4 was measured in unpurified urine samples by
direct enzyme immunoassay (Cayman Chemical, Ann
Arbor, MI). Supernatants of freshly collected spot urine
samples were stored at − 80°Celsius for not longer than
6 months. After thawing at 4 °C, urine was diluted in
phosphate buffered saline (1:10). The measurement was
repeated using 1:30 dilution of urine for samples in
which the LTE4 concentration exceeded the uppermost
calibrator concentration of the assay (1000 pg/mL). Re-
sults of urinary LTE4 measurements were expressed in
picograms per mg of creatinine.
Statistical analyses
Quantitative characteristics of the study population were
described using mean and standard error, while categor-
ical characteristics were described using means and per-
cents. Groups were compared with respect to baseline
quantitative characteristics and marker levels among the
groups with t-tests and analyses of variance for approxi-
mately normally distributed variables, while the Wilcoxon
rank-sum test was used with respect to variables demon-
strating non-normal distributions. Groups were compared
using the likelihood-ratio χ2 test with respect to categor-
ical variables. To evaluate uBrTyr, uLTE4, and blood eo-
sinophils as biomarkers for AERD diagnosis, cut-points
were used. A receiver operating characteristic (ROC) ana-
lysis was used to identify an optimal cut-point for uBrTyr
and uLTE4. A cut-point for blood eosinophils > 300 cells/
μL was based on published data [21, 22]. Logistic
regression was used to estimate odds ratios for the identi-
fication of AERD (vs ATA) with respect to the dichoto-
mized forms of the biomarkers. The logistic regression
analyses were also performed with covariate adjustment
for baseline FEV1%, chronic rhinosinusitis, and any steroid
use was performed with the logistic regression modeling.
The incremental predictive ability of each marker in the
regression model was assessed using areas under the ROC
curves estimated with 10-fold cross-validation for the full
model and for models excluding markers individually.
Correlations among quantitative variables were assessed
using Spearman’s rank-sum correlation coefficients, which
are suitable for data with any distribution. A p-value less
than or equal to 0.05 was defined as statistically
significant.
Results
Subject characteristics
The study included 240 patients with AERD, 226 pa-
tients with ATA, and 71 HC. Almost the same popula-
tion has been previously described [11]. The clinical
characteristics of the study subjects are shown in
Table 1. Age and gender were distributed significantly
differently in asthmatics, i.e., AERD and ATA when com-
pared to (HC), but no difference between AERD and ATA
was found. (Table 1). The AERD subjects had worse lung
functions and significantly longer asthma duration than
the ATA subjects (Table 1). Medication use was different
between the AERD and the ATA groups. No difference
was found with respect to the ACT scores (Table 1).
Asthma biomarkers
Both AERD and ATA groups had significantly higher
levels of uBrTyr, uLTE4, and blood eosinophils than HC
(Fig. 1). Furthermore, uLTE4 levels and blood eosino-
phils were significantly higher in AERD as compared to
ATA (p < 0.0001, p = 0.004, respectively), whereas uBrTyr
levels were not significantly different between these two
asthmatic phenotypes (p = 0.3406) (Fig. 1).
UBrTyr and uLTE4 levels correlated with each other
both in the AERD [R = 0.160, p = 0.01] and the ATA
[R = 0.151, p = 0.02] groups. Blood eosinophils corre-
lated significantly with uLTE4 levels in both asthma
phenotypes [ATA: R = 0.165, p = 0.01; AERD: R =
0.276, p < 0.0001], whereas no such correlation was
found with eosinophil counts and uBrTyr levels.
Both uBrTyr and uLTE4 levels did not correlate with
severity of airway obstruction measured by FEV1% pre-
dicted and FEV1%FVC in either asthma phenotype,
while only a borderline correlation was found between
FEV1%FVC and uLTE4 in ATA [R = 0.140, p = 0.05].
To evaluate if studied biomarkers have the ability to
predict an AERD diagnosis, values for each biomarker
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were dichotomized at cutoffs derived from ROC curve
analyses. The cutoff value for uBrTyr was 0.101 ng/mg
Cr (specificity 37%, sensitivity 70%), and the cutoff value
for uLTE4 was 800 pg/mg Cr (specificity 81%, sensitivity
50%). A high level of uBrTyr did not confer greater odds
of having AERD (OR 1.3; 95% Cl 0.9–2.0, p = 0.15)
(Fig. 2). The odds ratio for predicting AERD with respect
to blood eosinophils > 300 cells/uL was 1.8 (95% CI 1.2–
2.6, p = 0.003) (Fig. 2). A high level of uLTE4 > 800 pg/mg
Cr conferred 4.1-fold odds of having AERD (95% CI 2.7–
6.3; p < 0.0001). The combination of high blood eosino-
phils together with high uLTE4 levels increased the odds
for AERD diagnosis 6.0-fold (95% CI 3.4–10.9, p < 0.0001),
with frequency of AERD of 79.6% (74/93) among asth-
matics with both characteristics versus 39.5% (77/195)
among patients with neither characteristic. Asthmatics
with a combination of high blood eosinophil counts,
uLTE4 levels, and uBrTyr levels had 7.1 times greater odds
to have AERD than patients with none of the biomarkers
elevated (95% CI 3.4–15.8, p < 0.0001) (Fig. 2), with fre-
quency of AERD of 83.1% (59/71) among asthmatics with
all three characteristics versus 41.0% (32/78) among
patients with none of the characteristics. In the multivari-
able model with all 3 biomarkers, uBrTyr did not show
Table 1 Participant characteristics
AERD [n = 240] ATA
[n = 226]
Control
[n = 71]
p-value
(ANOVA)
T-Test
Demographics
Age (yrs) 49.3 [0.8] 49.7 [1.0] 44.3 [1.6] 0.008
Gender [M/F] 74/166 68/158 35/36 0.007
BMI (kg/m2) 26.7 [0.3] 27.1 [0.4] 25.6 [1.0]
Duration of asthma (yrs) 18.8 [0.8] 15.2 [1.0] n/a < 0.0001
ACT; uncontrolled, n [%] 108 [46] 98 [46] n/a
Medication use
High dose ICS/Oral CS, n (%) 63 (26) 37 (18) n/a 0.03
High dose ICS > 500 (μg/d), n (%) 62 (26) 52 (25.5) n/a
Low dose ICS ≤500 (μg/d), n (%) 78 (33) 92 (44.7) n/a 0.008
No ICS or Oral CS, n (%) 3 (14) 25 (12.4) n/a
Lung functions
FEV1% predicted 79.8 [1.3] 86.6 [1.4] n/a 0.0003
FEV1 %FVC 68.8 [0.7] 74.8 [0.7] n/a < 0.0001
Mean (SEM); Definition of abbreviations: AERD Aspirin-Exacerbated Respiratory Disease, ATA Aspirin Tolerant Asthma, M Male, F Female, BMI Body mass index, FEV1
Forced expiratory volume in 1 s, FVC Forced vital capacity, CS Corticosteroidsm, ICS Inhaled Corticosteroids
Fig. 1 Asthma biomarkers in AERD, ATA and control subjects. Evaluation of urinary BrTyr, urinary LTE4, and blood eosinophils in patients with
Aspirin-Exacerbated Respiratory Disease (AERD) (n = 240), patients with Aspirin-Tolerant Asthma (ATA) (n = 222), and control subjects (n = 68). All
markers were significantly different between the three groups (ANOVA, p < 0.05). Urinary BrTyr was the only biomarker not significantly different
between ATA and AERD (p > 0.05)
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statistically significant evidence of an additive benefit for
predicting AERD when uLTE4 and blood eosinophils were
already taken into account [adjusted odds ratio 1.1, 95%
CI 0.8–1.7, p = 0.57].
When performing further covariate adjustment for
baseline FEV1%, chronic rhinosinusitis, and steroid use,
the combination of high blood eosinophils together with
high uLTE4 levels increased the odds for AERD diagno-
sis 3.5-fold (95% CI 1.7–7.4, p = 0.0007), which was
smaller than the 6.0-fold estimate without the additional
covariate adjustments. Asthmatics with a combination of
high blood eosinophil counts, uLTE4 levels, and uBrTyr
levels had covariate-adjusted 7.7 times greater odds to
have AERD than patients with none of the biomarkers
elevated (95% CI 2.8–24.7, p = 0.0002), which was
slightly higher than the 7.1-fold estimate obtained with-
out the additional covariate adjustments. The additive
benefit of uBrTyr for predicting AERD when uLTE4 and
blood eosinophils were already taken into account also
jumped upward a bit [adjusted odds ratio 1.5, 95% CI
0.9–2.5, p = 0.09] when adjusting for the additional co-
variates, compared to the 1.1-fold increase estimated
without the additional adjustments. The adjustment for
steroid use was also performed with respect to only high
dose steroid use, but the odds ratio estimates for the
biomarkers was virtually identical to those obtained with
the adjustment for any steroid use. Using ROC curves,
10-fold cross-validated AUC estimates were 0.82 for the
full model and for models excluding either uBrTyr or
blood eosinophils, while the exclusion of uLTE4 yielded
an estimate of 0.79. This is not surprising given that
among the biomarkers, only uLTE4 levels yielded a sta-
tistically significant association with AERD when adjust-
ing for the other biomarkers and the selected covariates.
The cutpoint for uBrTyr level to predict asthma re-
gardless of phenotype was > 0.17 ng/mg Cr (specificity,
79%; sensitivity, 45%). Subjects with baseline uBrTyr
levels > 0.17 ng/mg Cr were 3.1 times (95% CI 1.7–5.8],
p > 0.0002) as likely to have asthma.
Discussion
Aspirin challenge is currently considered as the gold
standard and the only reliable method for the diagnosis
of AERD. However, due to certain limitations of this
procedure, an intensive search for in vitro diagnostic
biomarkers useful in identifying patients with AERD is
underway.
Novel biomarkers such as serum periostin [23], plasma
eosinophil-derived neurotoxin [24], serum levels of
LTE4, and LTE4/PGF2 alfa ratio [25] have been suggested
but are not routinely done as in vitro diagnostic tests.
They require verification in further studies.
As the imbalance of arachidonic acid metabolism and
increased inflammation are important pathophysiologic
features of AERD, we investigated if a panel of bio-
markers reflecting these imbalances could be used for
the prediction of this asthma phenotype. The current
study confirmed previous reports that uLTE4 levels and
Fig. 2 Odds ratios and 95% confidence intervals for the association between the presence of elevated marker levels, individually and in combination,
versus the diagnosis of AERD. Results shown represent the ORs (filled circles) and 95% CI (lines) of having AERD versus ATA (open circles) for participants
with high levels of urinary BrTyr and/or high levels of blood eosinophils, and/or high levels of urinary LTE4 compared with participants with low levels
of these markers. Asterisk indicates P < 0.05
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blood eosinophil counts are increased in AERD patients
as compared with ATA patients [9, 11, 26–28]. Addition-
ally, it revealed that both elevated blood eosinophil
count and increased uLTE4 levels separately enhanced
the chance of AERD diagnosis 1.8-fold and 4.2-fold, re-
spectively. The novel finding is that the combination of
these two biomarkers powers that prediction 6.0-fold.
Recently, Bochenek et al. demonstrated that a set of
clinical parameters comprising nasal polyps, upper air-
way symptoms, nasal corticosteroid treatment, asthma
exacerbations, FEV1% predicted, and age of asthma on-
set had a superior accuracy in the prediction of AERD
diagnosis to the measurement of uLTE4 level alone [11].
Addition of high uLTE4 level to clinical parameters
slightly enhanced the prediction of such diagnosis.
Ban et al. analyzed a metabolite profile that involved
the arachidonic acid pathway for discriminating AERD
from ATA and revealed that serum levels of LTE4 and
even more so LTE4/PGF2α ratio can be potential in vitro
diagnostic biomarkers for AERD [25]. Thus, similarly to
the current study, the combination of two biomarkers
together improved the diagnostic value of the test.
Eosinophils and mast cells play an important role in
the pathogenesis of AERD [7]. Studies have suggested
that eosinophils in AERD are driving cysteinyl leukotri-
enes overproduction and eosinophils proteins, e.g. ECP
increased following aspirin provocation fast [29, 30].
Previous findings showed that uBrTyr can be used as (1)
a molecular fingerprint of eosinophil activation; (2) a
predictor of asthma and asthma exacerbation; and (3) a
biomarker for asthma severity and corticosteroid respon-
siveness [15, 16, 31–34]. Despite serving as a marker for
eosinophil activation, uBrTyr levels did not correlate
with the amount of blood eosinophils found in either
the AERD or in the ATA group. The study by Mita et al.
on very small groups of patients with AERD (n = 12),
ATA (n = 12), and control subjects (n = 18) showed also
that higher uBrTyr levels in asthmatics were not related
to the presence of aspirin sensitivity, but rather to their
asthma alone [35]. As shown previously with asthmatic
adult and pediatric populations [31, 32, 35], in our co-
hort of adult asthmatics uBrTyr levels were also in-
creased in asthma when compared with HC and could
be used as a biomarker of asthma. However, a higher
uBrTyr level alone cannot distinguish patients with
AERD from patients with ATA, and thus it cannot be
used as a single parameter helpful in the diagnosis of
AERD. The multivariable modeling conducted presently
demonstrates a slight predictive benefit of uBrTyr level
in addition to the use of elevated blood eosiniphils and
elevated uLTE4 that is enhanced with covariate adjust-
ment for FEV1%, chronic rhinosinusitis, and steroid use,
though not reaching a magnitude of statistical signifi-
cance (p = 0.09).
Conclusion
This study reveals that uBrTyr levels are increased both
in AERD and in ATA but cannot identify AERD. This
suggested that the activation and the role of eosinophils
in the controlled asthma is similar regardless aspirin
hypersensitivity. The addition of uBrTyr to elevated
uLTE4 levels and blood eosinophils did not statistically
enhance the prediction of AERD diagnosis.14.
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